UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial

Annals of oncology, 2014-06, Vol.25 (6), p.1128-1136

2014

Volltextzugriff (PDF)

Breast cancer (BC) treatment (tx) with everolimus (EVE) and exemestane (EXE) in hormone receptor positive (HR+)/ HER2-negative (HER2−) postmenopausal women: Final analysis of the French observational TANGO study

Annals of oncology, 2018-10, Vol.29, p.viii109-viii109

2018

Volltextzugriff (PDF)

Clinical and pathologic characteristics of breast cancer patients carrying the c.3481_3491del11 mutation

Familial cancer, 2019-01, Vol.18 (1), p.1-8

2019

Volltextzugriff (PDF)

PALB2, a major susceptibility gene for breast cancer

Gynécologie, obstétrique, fertilité & sénologie, 2018-11, Vol.46 (10-11), p.701-705

2018

Volltextzugriff (PDF)

Is there a genetic anticipation in breast and/or ovarian cancer families with the germline c.3481_3491del11 mutation?

Familial cancer, 2018, Vol.17 (1), p.5-14

2018

Volltextzugriff (PDF)

Breast cancer management: The change is now!

Gynécologie, obstétrique, fertilité & sénologie, 2017-01, Vol.45 (1), p.3-4

2017

Volltextzugriff (PDF)

Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group Results

Annals of oncology, 2006-01, Vol.17 (1), p.85-92

2006

Volltextzugriff (PDF)

Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics

Genetics in medicine, 2010-12, Vol.12 (12), p.801-807

2010

Volltextzugriff (PDF)

Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas : Results of a french society of paediatric oncology phase II study

Cancer, 2005-12, Vol.104 (12), p.2792-2797

2005

Volltextzugriff (PDF)

Observational study of ferric carboxymaltose (FCM) in france (oncofer study; interim analysis)

Value in health, 2013-05, Vol.16 (3), p.A112-A112

2013

Volltextzugriff (PDF)

PCN28 COST SAVINGS WITH FERRIC CARBOXYMALTOSE THROUGH ITS IMPACT ON ERYTHROPOÏESIS-STIMULATING AGENTS AND BLOOD TRANSFUSION IN CHEMOTHERAPY-INDUCED ANEMIA OF BREAST AND GASTROINTESTINAL CANCER: FRENCH HEALTH CARE PAYER PERSPECTIVE

Value in health, 2011, Vol.14 (3), p.A159-A160

2011

Volltextzugriff (PDF)

Biosimilar epoetin for the management of chemotherapy-induced anaemia in elderly patients: a subanalysis of the ORHEO study

Journal of geriatric oncology, 2013-10, Vol.4, p.S82-S82

2013

Volltextzugriff (PDF)

PMD4 PERCEPTION OF IRON DEFICIENCY IN CLINICAL PRACTICES: MULTIDISCIPLINARY FRENCH SURVEY (SUPFER SURVEY)

Value in health, 2011, Vol.14 (3), p.A79-A79

2011

Volltextzugriff (PDF)

Techniques and complications of non-genetic risk reducing mastectomies: Guidelines of the National College of French Gynecologists and Obstetricians (CNGOF)

Gynécologie, obstétrique, fertilité & sénologie, 2022-02, Vol.50 (2), p.121-129

2022

Volltextzugriff (PDF)

High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: Final results of a phase II study

Annals of oncology, 2001-03, Vol.12 (3), p.397-404

2001

Volltextzugriff (PDF)

French women’s breast self-examination practices with time after undergoing BRCA1/2 genetic testing

Familial cancer, 2012-06, Vol.11 (2), p.269-278

2012

Volltextzugriff (PDF)

Abstract P1-10-02: Usage of epoetin alfa biosimilars in the management of chemotherapy-induced anemia in patients with breast cancer: A subanalysis of the ORHEO study

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P1-P1-10-02

2016

Volltextzugriff (PDF)

Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials

Annals of oncology, 2006-01, Vol.17 (1), p.65-73

2006

Volltextzugriff (PDF)

PALB2, gène majeur de susceptibilité au cancer du sein

Gynécologie Obstétrique Fertilité & Sénologie, 2018-11, Vol.46 (10-11), p.701-705

2018

Volltextzugriff (PDF)

ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer

Annals of oncology, 2005-01, Vol.16 (suppl-1), p.i7-i9

2005

Volltextzugriff (PDF)

uPA/PAI-1, Oncotype DX™, MammaPrint® Valeurs pronostique et prédictive pour une utilité clinique dans la prise en charge du cancer du sein

Oncologie (Paris, France), 2014, Vol.16 (4), p.196-206

2014

Volltextzugriff (PDF)

Epirubicin-Based Chemotherapy in Metastatic Breast Cancer Patients: Role of Dose-Intensity and Duration of Treatment

Journal of clinical oncology, 2000-09, Vol.18 (17), p.3115-3124

the French Epirubicin Study Group

2000

Volltextzugriff (PDF)

Oncogénétique: estimation des besoins de la population en France pour les dix ans à venir

Bulletin du cancer, 2009-09, Vol.96 (9), p.875-900

2009

Volltextzugriff (PDF)

Cancer genetics: estimation of the needs of the population in France for the next ten years

Bulletin du cancer, 2009-09, Vol.96 (9), p.875

2009

Volltextzugriff (PDF)

1 – 25 von 157

Suche als RSS-Feed

Aktive Filter

KollektionElsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(139)
Mit Volltextzugriff
(132)

Publikationsform

Artikel
(155)
Tagungsberichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial

Breast cancer (BC) treatment (tx) with everolimus (EVE) and exemestane (EXE) in hormone receptor positive (HR+)/ HER2-negative (HER2−) postmenopausal women: Final analysis of the French observational TANGO study

Clinical and pathologic characteristics of breast cancer patients carrying the c.3481_3491del11 mutation

PALB2, a major susceptibility gene for breast cancer

Is there a genetic anticipation in breast and/or ovarian cancer families with the germline c.3481_3491del11 mutation?

Breast cancer management: The change is now!

Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group Results

Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics

Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas : Results of a french society of paediatric oncology phase II study

Observational study of ferric carboxymaltose (FCM) in france (oncofer study; interim analysis)

PCN28 COST SAVINGS WITH FERRIC CARBOXYMALTOSE THROUGH ITS IMPACT ON ERYTHROPOÏESIS-STIMULATING AGENTS AND BLOOD TRANSFUSION IN CHEMOTHERAPY-INDUCED ANEMIA OF BREAST AND GASTROINTESTINAL CANCER: FRENCH HEALTH CARE PAYER PERSPECTIVE

Biosimilar epoetin for the management of chemotherapy-induced anaemia in elderly patients: a subanalysis of the ORHEO study

PMD4 PERCEPTION OF IRON DEFICIENCY IN CLINICAL PRACTICES: MULTIDISCIPLINARY FRENCH SURVEY (SUPFER SURVEY)

Techniques and complications of non-genetic risk reducing mastectomies: Guidelines of the National College of French Gynecologists and Obstetricians (CNGOF)

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: Final results of a phase II study

French women’s breast self-examination practices with time after undergoing BRCA1/2 genetic testing

Abstract P1-10-02: Usage of epoetin alfa biosimilars in the management of chemotherapy-induced anemia in patients with breast cancer: A subanalysis of the ORHEO study

Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials

PALB2, gène majeur de susceptibilité au cancer du sein

ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer

uPA/PAI-1, Oncotype DX™, MammaPrint® Valeurs pronostique et prédictive pour une utilité clinique dans la prise en charge du cancer du sein

Epirubicin-Based Chemotherapy in Metastatic Breast Cancer Patients: Role of Dose-Intensity and Duration of Treatment

Oncogénétique: estimation des besoins de la population en France pour les dix ans à venir

Cancer genetics: estimation of the needs of the population in France for the next ten years

Aktive Filter

Suchergebnisse filtern